. Author manuscript; available in PMC: 2017 Jun 12.

Published in final edited form as: Bone Marrow Transplant. 2016 Dec 12;52(3):400–408. doi: 10.1038/bmt.2016.265

Table 4a.

Summary of studies analyzing risk factors for acute GVHD after UCBT

Study	Population	Incidence of grades II–IV acute GVHD	Incidence of grades III–IV acute GVHD	Risk Factors
Macmillan et al.¹¹	Single UCBT (n=80)	39%	18%	Use of 2 UCB units NMA conditioning regimen No ATG
Macmillan et al.¹¹	Double UCBT (n=185)	58%	19%	Use of 2 UCB units NMA conditioning regimen No ATG
Lazaryan et al.¹⁰	Single UCBT (n=295)	26%	7%	Age ≥ 18 Higher HLA-mismatch^a
Lazaryan et al.¹⁰	Double UCBT (n=416)	56%	21%	No ATG^a Year of UCBT 2006 or later^a Higher HLA-mismatch^b Myeloablative conditioning^b
Ponce et al.¹³	Double UCBT (n=115)	53%	23%	Higher HLA-mismatch^b
Xavier et al.¹²	Double UCBT (n=921)	36%	15%	Myeloablative conditioning^a Higher HLA-mismatch^a No ATG Advanced disease stage^b
Chen et al.	Single UCBT (n=810)	39%	18%	No ATG
Chen et al.	Double UCBT (n=594)	45%	22%	No ATG^a Myeloablative conditioning

Abbreviations: GVHD = graft-vs.-host disease; UCBT = umbilical cord blood transplantation; UCB = umbilical cord blood; NMA = non-myeloablative; ATG = anti-thymocyte globulin; HLA = human leukocyte antigen; iv-TCD = in vivo T-cell depletion

Only for grades II–IV acute GVHD

Only for grades III–IV acute GVHD